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Abstract
Objective: To examine the timing and duration of RSV bronchiolitis hospital admission among term and preterm infants in
England and to identify risk factors for bronchiolitis admission.
Design: A population-based birth cohort with follow-up to age 1 year, using the Hospital Episode Statistics database.
Setting: 71 hospitals across England.
Participants: We identified 296618 individual birth records from 2007/08 and linked to subsequent hospital admission
records during the first year of life.
Results: In our cohort there were 7189 hospital admissions with a diagnosis of bronchiolitis, 24.2 admissions per 1000
infants under 1 year (95%CI 23.7–24.8), of which 15% (1050/7189) were born preterm (47.3 bronchiolitis admissions per
1000 preterm infants (95% CI 44.4–50.2)). The peak age group for bronchiolitis admissions was infants aged 1 month and
the median was age 120 days (IQR = 61–209 days). The median length of stay was 1 day (IQR = 0–3). The relative risk (RR) of a
bronchiolitis admission was higher among infants with known risk factors for severe RSV infection, including those born
preterm (RR = 1.9, 95% CI 1.8–2.0) compared with infants born at term. Other conditions also significantly increased risk of
bronchiolitis admission, including Down’s syndrome (RR = 2.5, 95% CI 1.7–3.7) and cerebral palsy (RR = 2.4, 95% CI 1.5–4.0).
Conclusions: Most (85%) of the infants who are admitted to hospital with bronchiolitis in England are born at term, with no
known predisposing risk factors for severe RSV infection, although risk of admission is higher in known risk groups. The early
age of bronchiolitis admissions has important implications for the potential impact and timing of future active and passive
immunisations. More research is needed to explain why babies born with Down’s syndrome and cerebral palsy are also at
higher risk of hospital admission with RSV bronchiolitis.
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Introduction
Acute bronchiolitis is the most common lower respiratory tract
infection (LRTI) in infants affecting around 10% of children under
1 year [1–5]. It is usually a mild, self-limiting illness but in some
infants may be more severe, requiring hospital admission.
Bronchiolitis is typically caused by respiratory syncytial virus
(RSV) in around 75% of cases [6], with peak incidence during the
winter months. Bronchiolitis admission rates in infants under 1
year have previously been estimated from small regional studies to
be 30?8 per 1000 in the United Kingdom (UK) [3] and 31?2 per
1000 in the United States (US) [7]. To date, no national studies
have reported the disease burden at a population level in the UK.
Children known to be at high risk of developing severe RSV
infection include those with chronic lung disease, congenital heart
disease, immunodeficiency, low birth weight and those born
preterm (approximately 8% of newborns in the UK) [8–11]. Other
factors associated with RSV infection include winter births,
poverty, malnutrition, tobacco smoke exposure, lack of breast-
feeding and multiple gestation [12]. Evidence from the US
suggests most children admitted to hospital with RSV infection are
healthy, with no risk factors for severe RSV infection [9].
Since there is no effective drug treatment, the mainstay of
management for infants with RSV bronchiolitis is supportive care
and a small proportion of more severely affected infants are
treated in intensive care [1,13–15]. Prophylactic passive immu-
notherapy with Palivizumab (SynagisH, MedImmune), a mono-
clonal antibody against RSV infection, is licensed for use in some
countries for those most at high risk of RSV infection, but is very
expensive (the estimated cost for a single dose of Palivizumab for
an infant aged 6 months, weighing 7?5 kg, is £1023?11 [16] so the
total cost for 5 doses over the winter season is just over £5000 per
patient). The Joint Committee for Vaccination and Immunisation
(JCVI) in the UK states Palivizumab use is only cost-effective for a
small group of infants at most risk of severe disease [16–18], but
there remains a poor evidence base of prognostic factors for
hospital admission due to RSV infection [18]. An active
immunisation against RSV is currently in phase III trials, also
aimed primarily at high-risk groups. However, the difficulty of
eliciting immunity in such young infants remains a challenge. The
aim of this study was to examine which infants are most at risk of
an RSV bronchiolitis admission in England in term, preterm and




Hospital Episodes Statistics (HES) is a national administrative
database, electronically recording all admissions to NHS hospitals
in England since 1989 (www.hesonline.nhs.uk) [19] and has been
used extensively for research and measuring quality of healthcare
delivery [20,21]. Annual reports from the Office for National
Statistics suggest that around 97% of all live births in England
occur in NHS hospitals. Coders enter information about clinical
diagnoses undertaken using the International Classification of
Diseases 10th revision (ICD-10). Maternity data in HES consists of
delivery records (for mothers) and birth records (for babies). These
contain additional data fields known as the ‘‘baby tail’’, which
include information such as birth weight and gestational age [22–
24].
Study cohort
We created a birth cohort for all infants born in English NHS
hospitals and discharged during a twelve month period (from 1st
April 2007 to 31st March 2008). We included only records from
live births and excluded infants born in hospitals (85/156) with
poor recording (,90% complete) of key indicators (birth weight
and gestational age), to enable us to group infants into term and
preterm categories [24]. Sensitivity analyses of number of
maternity beds, annual number of births, geographic location
and infant death rate were conducted to compare hospitals in the
study with sites excluded because of poor recording [24]. We
linked birth records to subsequent hospital admission records up to
a child’s first birthday, using a unique personal identifier (HES
ID). Linkage to Office of National Statistics (ONS) mortality
records allowed us to identify any deaths among the birth cohort
during their first year of life, including out-of-hospital deaths.
Outcome and exposure measures
Diagnostic information recorded in individual birth records and
any subsequent hospital admission records from the study year was
used to group infants into categories of risk factors for severe RSV
infection (Appendix S1) using ICD-10 codes or larger subgroups
using the Agency for Health Research and Quality’s Clinical
Classification System (CCS) [25]. Infants were considered preterm
if their gestational age at birth was less than 37 weeks (Appendix
S1), in accordance with the World Health Organisation (WHO)
definition of premature birth [26]. Infants missing gestational age
were assumed to be born at full term.
We identified infants admitted as an emergency with a primary
diagnosis of acute bronchiolitis using the ‘J21’ ICD-10 codes
(‘J210’ - acute bronchiolitis due to respiratory syncytial virus,
‘J218’ - acute bronchiolitis due to other specified organisms and
‘J219’ - acute bronchiolitis, unspecified). Most bronchiolitis
admissions were coded with unspecific aetiology and approxi-
mately a third were coded as being due to RSV. We grouped all
bronchiolitis codes into a single ‘‘RSV bronchiolitis’’ category as
RSV is the commonest cause of bronchiolitis, but specific
microbiological diagnoses are poorly coded in HES. We excluded
bronchiolitis admissions in children over 1 year because of the
uncertain nature of this clinical diagnosis in older infants. We
defined infants as being under 1 year of age. We examined age at
bronchiolitis admission and calculated the median length of stay
(LOS) for bronchiolitis admissions to provide a proxy measure of
severity of illness.
Statistical analyses
We calculated the absolute risk of a bronchiolitis admission
among infants with and without risk factors for severe RSV
infection, including preterm infants and infants with a clinical
diagnosis of cystic fibrosis, congenital heart disease, nervous system
congenital anomalies, other congenital anomalies, immunodefi-
ciency, cerebral palsy or Down’s syndrome (case definitions and
codes in Appendix S1). Infants without a particular risk factor
condition were considered ‘‘healthy’’. Associated 95% confidence
intervals (CI) were calculated using Poisson approximation. We
calculated the relative risk (RR) of a bronchiolitis admission, with
associated 95% CI for infants in each individual risk group, by
comparing with the baseline group of infants without the
particular risk factor. Infants may belong to more than 1 of these
risk groups, so we controlled for this potential confounding using
Poisson regression models to calculate the adjusted RR of
bronchiolitis admission for infants in each risk group. To test for
significant differences between proportions we used Chi Squared
tests and Mann-Whitney tests to compare median values for non-
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normal data. Data were analysed using the SAS 9?2 software
package (SAS Institute, Cary, N.C., USA).
Research Ethics approval
We have permission from the National Information Gover-
nance Board (NIGB) under Section 251 of the NHS Act 2006
(formerly Section 60 approval from the Patient Information
Advisory Group) to hold confidential data. We have approval to
use them for research and measuring quality of delivery of
healthcare, from the South East Ethics Research Committee.
Results
The birth cohort included 296618 infants, from 71 NHS
hospitals in England. 410 infants in the cohort died during the
study year. 51% (151897/296618) of the cohort were boys, 1%
(2891) were multiple births and 7?5% (22215) were born preterm
before 37 weeks gestation (Table S2, Appendix S2).
Among our birth cohort there were 7189 admissions to hospital
with a primary diagnosis of bronchiolitis during their first year of
life, 24?2 admissions per 1000 infants (95% CI 23?7 to 24?8). Only
2015 (28?0%) of these were specifically coded as being due to
RSV, the remainder were unspecified. In total, 1529 (21?3%)
infants admitted with bronchiolitis, had more than one bronchi-
olitis admission during their first year of life. The modal age of
bronchiolitis admission was 1 month (Figure 1) and the median
age was 120 days (Inter-quartile range (IQR) = 61 to 209). The
median length of hospital stay was 1 day (IQR=0 to 3 days).
Among infants admitted with bronchiolitis, 15% (1050/7189)
were born preterm. Admission rates were higher among infants
born preterm (47?3 per 1000 infants (95%CI 44?4–50?2))
compared with those born at term (22?4 per 1000 infants
(95%CI 21?8–22?9)) (Table 1). The median length of stay for a
bronchiolitis admission among infants born preterm was 1 day
(IQR=0 to 3) and among those born at term it was also 1 day
(IQR=0 to 3). The median age of the bronchiolitis admission
among infants born preterm was 136 days (IQR=71 to 221)
compared with 118 days (IQR=59 to 207) among infants born at
term (p,0?001).
Among infants admitted with bronchiolitis, 1722 (24?0%) had
one or more known risk factors for severe RSV infection. The
adjusted RR of a bronchiolitis admission was high among infants
with known risk factors for severe RSV disease, including those
born preterm (RR 1?9 (95%CI 1?8–2?0)) or with congenital heart
conditions (RR 3?4 (95%CI 2?9–3?8)) or chronic lung disease (RR
1?6 (95%CI 1?4–1?8)), compared with healthy infants without the
risk factor (Table 1). Other conditions also significantly increased
an infant’s risk of bronchiolitis admission, including cystic fibrosis
(RR=2?5 (95% CI 1?4 to 4?4)), Down’s syndrome (RR 2?5
(95%CI 1?7–3?7)), cerebral palsy (RR 2?4 (95%CI 1?5–4?0)) and
other nervous system congenital abnormalities (RR=1?7 (95% CI
1?3 to 2?4)). A higher proportion of infants born in September
(3?9%) or October (3?8%) were admitted with bronchiolitis than
among infants born in any other month (p,0?001). Bronchiolitis
admission rates among infants born in the North East (3?3%) and
Yorkshire and the Humber (3?3%) SHAs, were higher (p,0?001)
compared with in infants born in London (1?6%) (Figure 2).
Discussion
Main findings
Most (85%) of the infants who are admitted to hospital with
bronchiolitis in England are born at term, with no known
predisposing risk factors for severe RSV infection, although risk of
admission is higher in known risk groups. Babies born with
Down’s syndrome, cerebral palsy and cystic fibrosis are also at
higher risk of hospital admission with RSV bronchiolitis. The early
age of bronchiolitis admissions has important implications for the
potential impact and timing of future active and passive
immunisations.
Figure 1. Age of bronchiolitis admission in months, for admissions coded as RSV or unspecified bronchiolitis.
doi:10.1371/journal.pone.0089186.g001
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Strengths and weaknesses
This is among the first studies reporting the population burden
of bronchiolitis across NHS hospitals in England. The main
strength of our cohort is that use of HES birth records provides a
large, nationally representative sample of births across England
during this time, when compared with ONS live births data [27].
We assumed infants with unknown gestational age and birth
weight were not born preterm, as infants in this unknown group
had similarly short length of stay at birth to infants born at term.
Despite incomplete recording of gestational age in some birth
records, 7?5% of our cohort were born at ,37 weeks gestation
which is consistent with ONS data reporting that around 7?7% of
live births annually are delivered preterm [28]. This suggests
under-reporting of gestational age in HES birth records appears to
be mostly among term babies. Similarly, rates of congenital heart
disease, chronic lung disease and other risk factors for severe RSV
disease compare well with published UK population data
[3,29,30].
However, there are a number of important limitations to our
study. Our case definition for bronchiolitis and co-morbidity is
dependent on the accuracy of clinical coding and recording in
diagnosis fields in HES records, although improvements in the
quality of HES coding have been demonstrated in recent years
[31]. We combined RSV and unspecified bronchiolitis, presenting
data on all bronchiolitis admissions. Only 28% of the bronchiolitis
admissions were coded as being due to RSV, the remainder having

















infants under 1 year
(95% CIs) RR{ (95% CIs)
Adjusted RR
(95%CI)
Born at term 6139 (2?2) 274403 (92?5) 1 (0 to 3) 22?4 (21?8 to 22?9) – –
Premature birth 1050 (4?7) 22215 (7?5) 1 (0 to 3) 47?3 (44?4 to 50?2) 2?11 (1?98 to 2?26) 1.89 (1?77 to 2?02)
Cystic fibrosis 11 (6?4) 171 (0?1) 2 (0 to 14) 64?3 (32?1 to 115?1) 2?66 (1?33 to 4?76) 2?45 (1?36 to 4?43)
Congenital heart Disease 272 (12?1) 2239 (0?8) 2 (0 to 5) 121?5 (107?5 to 136?8) 5?17 (4?56 to 5?84) 3?35 (2?92 to 3?84)
Chronic lung disease 282 (5?6) 5016 (1?7) 2 (0 to 4) 56?2 (49?9 to 63?2) 2?37 (2?10 to 2?67) 1?61 (1?42 to 1?82)
Immunodeficiency 7 (11?7) 60 (0?0) 8 (1 to 58) 116?7 (46?9 to 240?4) 4?82 (1?94 to 9?93) 1?69 (0?80 to 3?58)
Nervous system congenital
anomalies
42 (8?6) 489 (0?2) 2 (1 to 4) 85?9 (61?9 to 116?1) 3?56 (2?56 to 4?82) 1?73 (1?26 to 2?36)
Down’s syndrome 28 (15?4) 182 (0?1) 3 (0 to 9) 153?9 (102?2 to 222?4) 6?37 (4?23 to 9?21) 2?53 (1?72 to 3?72)
Cerebral Palsy 16 (10?7) 149 (0?1) 3 (1 to 5) 107?4 (61?4 to 174?4) 4?44 (2?54 to 7?21) 2?43 (1?48 to 3?99)
{Relative risk compared with infants without risk factor of interest.
doi:10.1371/journal.pone.0089186.t001
Figure 2. Proportion of bronchiolitis hospital admissions among birth cohort, by Strategic Health Authority (SHA) of admission.
doi:10.1371/journal.pone.0089186.g002
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unspecific bronchiolitis codes. No linked microbiological data to
confirm the presence of RSV was available. A previous study in
the UK has estimated that around 75% of unspecified bronchi-
olitis admissions were RSV related [32]. Globally it is estimated
that only between 4% and 28% of children admitted with LRTI
are tested for RSV [4].
A limitation of the cohort study design is attrition, as it was not
possible to identify bronchiolitis admissions occurring outside
NHS hospitals in England, or to identify individuals who migrated
elsewhere, though we estimate this number should be low with
only one year of follow-up. Using linked ONS mortality data it was
possible to identify the small number of individuals in the cohort
who died during the study period. The number of infant deaths
directly attributable to RSV infection is reported to be very low
[33]. There is potentially some inherent selection bias in our study,
through the inclusion of only hospitals with good completeness of
recording of birth record fields, but sensitivity analyses showed few
differences between included and excluded sites in terms of supply
factors (such as number of maternity beds and number of
deliveries). No data were available to identify any individuals
who had received Palivizumab prophylaxis against RSV infection.
There are very strict criteria for Palivizumab use in the UK due to
its significant cost, which means that very few babies in the cohort
are likely to have received it.
Findings in relation to other studies
We found no comparable national studies to compare our
estimates of bronchiolitis hospital admission rates in the UK but
one previous study from Shropshire reported a bronchiolitis
hospital admission rate of 30?8 per 1000 infants in this region of
England [3], compared with our estimate of 24?2 admissions per
1000 infants. Our estimate may be slightly lower because we
applied a narrow case definition including only infants admitted
with a primary diagnosis of bronchiolitis (ICD-10 ‘J21’codes). This
is likely to underestimate the total burden of RSV illness in
infancy, as we have excluded pneumonias due to RSV and non-
specific, symptomatic clinical codes from our bronchiolitis case
definition, though some of these admissions may in reality have
been related to RSV infection. A study from the United States has
reported a bronchiolitis admission rate of 31?2 per 1000 infants
under 1 year [7], but a more recent study in Texas reported higher
bronchiolitis admission rates of 5?5% among children under 2
years [34]. These higher incidence estimates are likely to be due to
the wider inclusion of children aged 12 to 24 months in their
study, coupled with variation in the clinical definition of
bronchiolitis used in the US compared with that used in UK [13].
21% of infants admitted with bronchiolitis, had more than one
bronchiolitis admission during their first year of life. Previous
infection with RSV only confers partial immunity, so it is possible
for individuals to be re-infected with the same or different RSV
strains over the course of one season. Re-admissions for
bronchiolitis among older infants may in reality be incorrectly
diagnosed episodes of post-bronchiolitic wheezing. The modal age
of bronchiolitis admission was 1 month and the median was 4
months, confirming findings reported elsewhere which show
increased risk of RSV admission with younger age [13,35–37].
It is unclear why RSV may be affecting babies at a younger age
than has previously been reported. It could be associated with
changes to the virus itself or maternal immunological priming, but
further investigation into what may be driving this trend is needed.
The median age of bronchiolitis admission was 4 months which is
consistent with other studies where RSV hospital admissions are
typically reported during the first 3 to 6 months of life [8,38].
However, there is some debate regarding the most common age of
RSV admissions [37]. A population-based cohort in Denmark
found the median age of admission for RSV infections was 6
months [39]. Similarly, a recent prognostic birth cohort study
reported that the median age at time of RSV LRTI was 6 months
[40]. Unplanned short stay hospital admissions in this age group
have been increasing [20]. In 2006 the unplanned admission rate
among children less than 1 year in England was 181 per 1000
child years [20]. Our findings suggest that approximately 1 in 6 of
these unplanned admissions was for bronchiolitis.
We found the majority of infants admitted with bronchiolitis
were not in high-risk groups, with only 24% (1722/7189) having
one or more recognised risk factors for severe RSV infection. In a
smaller US study, 34% of RSV-infected patients (189/564) had at
least one high-risk condition for RSV infection [9]. Preterm infants
accounted for only 15% of bronchiolitis admissions in our study.
Infants with chronic lung disease or congenital heart disease each
accounted for around 4% of bronchiolitis admissions. This is
consistent with findings reported elsewhere, suggesting that the
majority of infants with severe RSV infection do not have any
underlying risk factors [9]. Low rates of bronchiolitis admissions in
some high-risk groups may also be driven by Palivizumab use,
however no national prescribing data for Palivizumab is available
for us to estimate the number of admissions its use may have
prevented. The median age of bronchiolitis admission was only 18
days later in preterm infants (136 days) compared with those born
at term (118 days), so onset of RSV disease appears to occur at a
similar corrected age. Median LOS for bronchiolitis admissions
was calculated as a proxy marker of severity of illness and was
found to be similarly short (1 day) among both term and preterm
born infants.
Geographical variation in bronchiolitis admission rates may be
a proxy for other risk factors for hospital admission with severe
RSV infection, such as maternal smoking or deprivation. We think
this finding is most likely driven by variation in clinical practice,
with different thresholds for admission in different regions as there
are no national evidence based guidelines giving criteria for
admission. Indeed, widespread variation in hospital management
of bronchiolitis has previously been reported [13].
Implications and future research
Our study has highlighted that the burden of RSV bronchiolitis
hospital admissions among infants in England predominantly
affects those born at term, without any risk factors for severe RSV
infection and the age at admission appears to be significantly lower
now than previously reported. Since the majority of infants
hospitalised with bronchiolitis are below 6 months of age, this will
limit the impact of any future vaccine which is unlikely to be
capable of eliciting immunity in such young infants. This has
important implications for future vaccination strategies, suggesting
that the cost benefit of both active and passive vaccines needs
detailed evaluation. We found that the median length of stay for
bronchiolitis admissions was only 1 day. Improved management of
symptoms in the community, through both primary care and A &
E services may reduce the need for admission still further. Further
studies examining the clinical burden of bronchiolitis in the
community are needed and could confirm the clinical and health
service burden to be greater still [13,16,18]. Improved manage-
ment of RSV is achievable through the use of improved, evidence-
based guidelines [1]. The regional variation in bronchiolitis
admission rates we have presented suggests admission criteria
vary widely and there is a need for clearer guidance about which
infants to admit to hospital in the UK.
Our findings suggest that in addition to the recognised risk
factors for RSV bronchiolitis hospital admission, namely congen-
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ital heart disease, chronic lung disease and preterm birth, several
other clinical conditions may also increase risk. The factors we
have identified are cerebral palsy, cystic fibrosis and Down’s
syndrome. We suggest further investigation is warranted, into
whether infants with these conditions would also benefit from
Palivizumab immunoprophylaxis.
Conclusion
Bronchiolitis is an important cause of hospital admissions
among infants in the UK. Several clinical subgroups are at
increased risk of hospital admission, but the majority of
bronchiolitis cases in England are among infants born at term,
with no known risk factors for severe RSV infection. The early age
of bronchiolitis admissions has important implications for the
potential impact of future active and passive immunisations. More
research is needed to explain why babies born with Down’s
syndrome and cerebral palsy are also at higher risk of hospital
admission with RSV bronchiolitis.
What’s known on this subject
Well known predisposing risk factors for RSV bronchiolitis
include preterm birth, chronic lung disease, congenital heart
disease and immune deficiency. Passive immunotherapy is
indicated for those at highest risk of severe infection.
What this study adds
Most infants admitted to hospital with bronchiolitis are born at
term and have no risk factors for severe RSV infection. There is a
peak in bronchiolitis admissions at the age of 1 month.
Research Ethics approval
We have permission from the NIGB under Section 251 of the
NHS Act 2006 (formerly Section 60 approval from the Patient
Information Advisory Group) to hold confidential data. We have
approval to use them for research and measuring quality of
delivery of healthcare, from the South East Ethics Research
Committee.
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